Neuren Pharmaceuticals (NEU.AX)

Executive Summary

Neuren Pharmaceuticals is an Australian biotech company focused on developing therapies for rare neurological disorders. Its lead product, DAYBUE (trofinetide), received FDA approval in March 2023 for Rett syndrome, marking a significant milestone. DAYBUE is the first and only approved treatment for Rett syndrome, addressing a high unmet medical need. The company is now generating revenue from DAYBUE sales and has a robust pipeline centered on NNZ-2591, a synthetic analog of cyclic glycine-proline (cGP) with potential in multiple neurodevelopmental disorders. NNZ-2591 has completed Phase 2 trials in Angelman syndrome and Pitt-Hopkins syndrome, with data expected to be presented in 2026. A Phase 3 trial for Phelan-McDermid syndrome (NCT07281079) began recruiting in late 2025, with completion targeted for 2027. Neuren also has earlier-stage programs in traumatic brain injury and other indications. The company's focus on rare diseases with clear regulatory pathways and its commercial-stage asset provide a foundation for growth. However, dependence on DAYBUE's commercial success and the risk of pipeline setbacks are key considerations. With a market capitalization of ~$1.6B, Neuren is positioned as a leader in rare CNS disorders, and upcoming data catalysts could drive significant value.

Upcoming Catalysts (preview)

• Q3 2026Phase 2 data readout for NNZ-2591 in Angelman syndrome80% success
• Q3 2026Phase 2 data readout for NNZ-2591 in Pitt-Hopkins syndrome80% success
• Q2 2027Enrollment completion in Phase 3 Phelan-McDermid syndrome trial70% success